The Belgian approach to BALLETT (Local Laboratory Extensive Tumor Testing) trials will recruit patients from 12 participating sites, who will be offered CGP from one of nine next-generation sequencing laboratories across Belgium.
Data from CGP will be used to determine the best therapeutic options for patients through access to targeted drugs to improve clinical outcomes in advanced cancer. The study will begin next month.
CGP uses next-generation sequencing (NGS) to analyze hundreds of genes and biomarkers in tissue and blood samples and identify those that are clinically relevant to cancer growth.
Illumina will provide its TruSight Oncology 500 (TSO500) CGP panel and its NovaSeq 6000 and NextSeq sequencing platforms for the study.
Dr. Sven Schaeffer, Head of Scientific Affairs at Illumina, told BioPharma Reporter, “There is already strong clinical evidence to show that CGP is helping to identify more cancer patients for highly effective genomic-guided therapies and that it does so in better patient outcomes can lead. .
“What is special about this study, which is carried out by the BSMO in nine Belgian test centers, is that the benefits of CGP are demonstrated in a real environment compared to the standard of care. This prospective, multicenter approach will help us to gain new / additional knowledge regarding feasibility, clinical benefit and acceptance by physicians. “
Detection of genes and biomarkers .
“With this new study, we want to ensure that patients across Belgium are receiving the right treatment for their cancer at the right time,” said Dr. Sylvie Rottey, chairwoman of the BSMO.
Dr. Brigitte Maes of the Jessa Hospital in Belgium, coordinator of the BALLETT study, said the study will provide valuable insight into the value of CGP compared to currently reimbursed sequencing approaches as part of the comprehensive Belgian approach to advancing precision medicine.
“In addition to genetic mutations that drive cancer development, CGP will, for example, also identify cancers that are triggered by the tumor mutation burden biomarker (TMB) and can lead patients to immunotherapeutic treatments. This means the study will provide access to additional treatments that more traditional diagnostic tests may not have included, “she said.
Genomic data, along with unidentified clinical data from the study, will be used to populate a newly established national genomic tumor database in Belgium, compiled under the supervision of the country’s Scientific Public Health Institute, Sciensano, to advance precision medicine and patients . Access to novel effective therapies.